News

Many adverse-event reports and safety signals linked to Amvuttra (vutrisiran) treatment for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) in real-world databases were consistent…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to coramitug, an experimental treatment in late-stage clinical testing for transthyretin…

Treatment with Wainua (eplontersen) was associated with slower disease progression and improved quality of life in both men and women with hereditary transthyretin…

A blood test measuring levels of the protein MR-proADM may help predict heart failure events (worsening of symptoms requiring immediate medical care) and death in…

Carpal tunnel syndrome (CTS) in both wrists may be a red flag of transthyretin amyloidosis (ATTR), including hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), a…

Starting Attruby (acoramidis) early and taking it continuously helps adults with transthyretin amyloid cardiomyopathy (ATTR-CM) live longer, stay out of the hospital for…

Amvuttra (vutrisiran) safely and effectively eases symptoms, reduces disability, and improves quality of life in East Asian adults with hereditary transthyretin amyloidosis with polyneuropathy…

People with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) are significantly more likely to have a history of agricultural work, manual labor, and greater upper-body physical…

Use of the approved therapy Wainua (eplontersen) effectively slows disease progression and improves quality of life among adults with hereditary transthyretin amyloidosis with…

Amvuttra (vutrisiran) was associated with improvements in quality of life and physical function in adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). That’s according…